Wikipedia

4-PrO-DMT

4-Propionoxy-N,N-dimethyltryptamine (4-PrO-DMT, or O-Propionylpsilocin) is a synthetic psychedelic drug from the tryptamine family with psychedelic effects, and is believed to act as a prodrug for psilocin.[1] It produces a head-twitch response in mice.[1] It has been sold online as a designer drug since May 2019. It was first identified as a new psychoactive substance in Sweden, in July 2019.[2] A number of related derivatives have been synthesized as prodrugs of psilocin for medical applications.[3]

4-PrO-DMT
Clinical data
Other names4-Propanoyloxy dmt
Identifiers
  • [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] propanoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H20N2O2
Molar mass260.337 g·mol−1
3D model (JSmol)
  • CCC(=O)OC1=CC=CC2=C1C(=CN2)CCN(C)C
  • InChI=1S/C15H20N2O2/c1-4-14(18)19-13-7-5-6-12-15(13)11(10-16-12)8-9-17(2)3/h5-7,10,16H,4,8-9H2,1-3H3
  • Key:KUOGXPDQORRHED-UHFFFAOYSA-N

Recreational use

edit
 
4-PrO-DMT Crystals

Dosage

edit

4-PrO-DMT is reported to be orally psychoactive substance and while dosage effects have been studied in mice, its effects and longevity on humans has not been formally studied. The effects of 4-PrO-DMT are similar to those of psilocin (4-HO-DMT), as it acts as a prodrug.[1][4]

Pharmacology

edit

Pharmacodynamics

edit

4-PrO-DMT is theorized to be a serotonergic psychedelic, and is partial agonist of the 5-HT1D, 5-HT1B and 5-HT1A serotonin receptors.[1][5]

Toxicity

edit

Very little data about the toxicity or pharmacology of 4-PrO-DMT is known. Its chemical structure and pharmacological activity are similar to psilacetin, a compound which isn't associated with compulsive use or physical dependence. However, due to lack of research and data, it cannot be definitively concluded that its pharmacological actions in the human body do not differ from those of psilacetin. To date, there have been no reported deaths from 4-PrO-DMT.[1]

See also

edit

References

edit
  1. ^ a b c d e Glatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, Baumann MH (April 2023). "Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice". ACS Pharmacology & Translational Science. 6 (4): 567–577. doi:10.1021/acsptsci.2c00222. PMC 10111620. PMID 37082754.
  2. ^ European Monitoring Center for Drugs and Drug Addiction (December 2020). New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262. ISBN 9789294975584. Archived (PDF) from the original on 2022-10-08. Retrieved 2021-06-17.
  3. ^ Raithatha SA, Hagel JM, Matinkhoo K, Yu L, Press D, Cook SG, et al. (November 2023). "Novel Psilocin Prodrugs with Altered Pharmacological Properties as Candidate Therapies for Treatment-Resistant Anxiety Disorders". Journal of Medicinal Chemistry. 67 (2): 1024–1043. doi:10.1021/acs.jmedchem.3c01225. PMC 10823477. PMID 37983270.
  4. ^ "Foundational Science for the Psilocybin Analog 4-PrO-DMT in Mice". CaaMTech. 28 March 2023. Archived from the original on 2024-03-03.
  5. ^ Greene, Shaun L. (2022-01-01), Dargan, Paul; Wood, David (eds.), "Chapter18 - Tryptamines", Novel Psychoactive Substances (Second Edition), Boston: Academic Press, pp. 495–532, doi:10.1016/b978-0-12-818788-3.00014-0, ISBN 978-0-12-818788-3, retrieved 2024-08-29
Retrieved from "https://en.wikipedia.org/w/index.php?title=4-PrO-DMT&oldid=1248805215"